GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanjing Medlander Medical Technology Co Ltd (SHSE:688273) » Definitions » Piotroski F-Score

Nanjing Medlander Medical Technology Co (SHSE:688273) Piotroski F-Score : 6 (As of May. 27, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nanjing Medlander Medical Technology Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Nanjing Medlander Medical Technology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Nanjing Medlander Medical Technology Co's Piotroski F-Score or its related term are showing as below:

SHSE:688273' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 6
Current: 6

During the past 6 years, the highest Piotroski F-Score of Nanjing Medlander Medical Technology Co was 6. The lowest was 5. And the median was 6.


Nanjing Medlander Medical Technology Co Piotroski F-Score Historical Data

The historical data trend for Nanjing Medlander Medical Technology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Medlander Medical Technology Co Piotroski F-Score Chart

Nanjing Medlander Medical Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A N/A 5.00 6.00

Nanjing Medlander Medical Technology Co Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 5.00 6.00 6.00 6.00

Competitive Comparison of Nanjing Medlander Medical Technology Co's Piotroski F-Score

For the Medical Devices subindustry, Nanjing Medlander Medical Technology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanjing Medlander Medical Technology Co's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanjing Medlander Medical Technology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Nanjing Medlander Medical Technology Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 26.457 + 25.895 + 5.08 + 36.286 = ¥93.7 Mil.
Cash Flow from Operations was 33.397 + 21.667 + 60.182 + 4.059 = ¥119.3 Mil.
Revenue was 95.278 + 86.055 + 50.369 + 104.337 = ¥336.0 Mil.
Gross Profit was 70.749 + 65.261 + 37.465 + 77.266 = ¥250.7 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(1508.429 + 1490.709 + 1500.254 + 1533.924 + 1554.515) / 5 = ¥1517.5662 Mil.
Total Assets at the begining of this year (Mar23) was ¥1,508.4 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2.1 Mil.
Total Current Assets was ¥1,107.3 Mil.
Total Current Liabilities was ¥122.4 Mil.
Net Income was 25.586 + 51.426 + 23.587 + 32.386 = ¥133.0 Mil.

Revenue was 108.563 + 115.186 + 78.57 + 109.123 = ¥411.4 Mil.
Gross Profit was 60.54 + 84.638 + 58.644 + 68.883 = ¥272.7 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(521.877 + 564.159 + 1518.042 + 1511.916 + 1508.429) / 5 = ¥1124.8846 Mil.
Total Assets at the begining of last year (Mar22) was ¥521.9 Mil.
Long-Term Debt & Capital Lease Obligation was ¥4.9 Mil.
Total Current Assets was ¥1,316.8 Mil.
Total Current Liabilities was ¥78.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Nanjing Medlander Medical Technology Co's current Net Income (TTM) was 93.7. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Nanjing Medlander Medical Technology Co's current Cash Flow from Operations (TTM) was 119.3. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=93.718/1508.429
=0.06212954

ROA (Last Year)=Net Income/Total Assets (Mar22)
=132.985/521.877
=0.25482058

Nanjing Medlander Medical Technology Co's return on assets of this year was 0.06212954. Nanjing Medlander Medical Technology Co's return on assets of last year was 0.25482058. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Nanjing Medlander Medical Technology Co's current Net Income (TTM) was 93.7. Nanjing Medlander Medical Technology Co's current Cash Flow from Operations (TTM) was 119.3. ==> 119.3 > 93.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=2.062/1517.5662
=0.00135875

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=4.942/1124.8846
=0.00439334

Nanjing Medlander Medical Technology Co's gearing of this year was 0.00135875. Nanjing Medlander Medical Technology Co's gearing of last year was 0.00439334. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=1107.348/122.444
=9.04370978

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=1316.819/78.272
=16.82362786

Nanjing Medlander Medical Technology Co's current ratio of this year was 9.04370978. Nanjing Medlander Medical Technology Co's current ratio of last year was 16.82362786. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Nanjing Medlander Medical Technology Co's number of shares in issue this year was 99.142. Nanjing Medlander Medical Technology Co's number of shares in issue last year was 99.988. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=250.741/336.039
=0.74616637

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=272.705/411.442
=0.66280302

Nanjing Medlander Medical Technology Co's gross margin of this year was 0.74616637. Nanjing Medlander Medical Technology Co's gross margin of last year was 0.66280302. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=336.039/1508.429
=0.22277416

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=411.442/521.877
=0.78838883

Nanjing Medlander Medical Technology Co's asset turnover of this year was 0.22277416. Nanjing Medlander Medical Technology Co's asset turnover of last year was 0.78838883. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Nanjing Medlander Medical Technology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Nanjing Medlander Medical Technology Co  (SHSE:688273) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Nanjing Medlander Medical Technology Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Nanjing Medlander Medical Technology Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanjing Medlander Medical Technology Co (SHSE:688273) Business Description

Traded in Other Exchanges
N/A
Address
No. 2, Gande Road, 2nd Floor, Building 5, Jiangning High-tech Park, Jiangning District, Jiangsu Province, Nanjing City, CHN, 211100
Nanjing Medlander Medical Technology Co Ltd is engaged in the research and development, production, sales and service of related products in the field of pelvic floor and postpartum rehabilitation.
Executives
Zhu Bi Sheng senior management
Chen Jiang Ning senior management
Yang Rui Jia Directors, senior managers, core technical personn
Shi Zhi Huai Directors, senior managers, core technical personn
Chen Bin Directors, senior managers
Tu Hong Lin Directors, senior managers
Wang Wang senior management

Nanjing Medlander Medical Technology Co (SHSE:688273) Headlines

No Headlines